TORONTO, July 26, 2023 /CNW/ - LifeSpeak Inc. ("LifeSpeak" or the "Company") (TSX: LSPK), the leading whole-person wellbeing solution for employers, health plans and other organizations, announced today that it will release its second quarter 2023 financial results before market open on Wednesday, August 9, 2023.
The Company will subsequently hold a conference call to provide a business update on Wednesday, August 9, 2023, at 8:00 a.m. ET hosted by:
A question-and-answer session will follow the business update.
CONFERENCE CALL DETAILS | |
DATE: | Wednesday, August 9, 2023 |
TIME: | 8:00 a.m. ET |
DIAL-IN NUMBERS: | 1.833.950.0062 or 1.833.470.1428 |
REFERENCE NUMBER: | 794729 |
This live call is also being webcast and can be accessed by going to: https://events.q4inc.com/attendee/320829741
An archived telephone replay of the call will be available for two weeks by dialing 1.226.828.7578 or 1.866.813.9403 and entering access code 526102.
LifeSpeak Inc. is the leading whole-person wellbeing solution for employers, health plans, and other organizations. LifeSpeak Inc.'s suite of digital solutions allows organizations to provide best-in-class content and expertise at scale, empowering individuals to live their healthiest lives. With a flexible portfolio of solutions, including LifeSpeak Mental Health & Resilience, LIFT session Fitness, ALAViDA Substance Use, Torchlight Parenting & Caregiving, and Wellbeats Wellness, LifeSpeak Inc. offers support across every pillar of wellbeing. LifeSpeak Inc. has more than 30 years of collective experience working with Fortune 500 companies, government agencies, insurance providers, and others across the globe. Insights from LifeSpeak Inc.'s digital and data-driven solutions uncover gaps in wellbeing at the individual and organizational levels, ultimately enhancing workplace performance outcomes. To learn more, follow LifeSpeak Inc. on LinkedIn (http://www.linkedin.com/ company/lifespeak-inc), or visit www.LifeSpeak.com.
| Last Trade: | C$0.37 |
| Daily Change: | -0.01 -2.63 |
| Daily Volume: | 9,500 |
| Market Cap: | C$21.880M |
November 07, 2024 May 08, 2024 March 21, 2024 | |
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MORE
Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MORE
